PeptiDex
Peptide Research Index
Research-backed
Peptide Research Index
⚠️ Educational only · Not medical advice · Consult a doctor · Most peptides are research-only / not FDA-approved for human use
⚠️ Educational only · Not medical advice · Consult a doctor · Most peptides are research-only / not FDA-approved for human use
Also: Ozempic, Wegovy, Rybelsus
🔥GLP-1 AgonistGLP-1 receptor agonism mimics the incretin hormone to reduce appetite, slow gastric emptying, improve insulin sensitivity, and provide cardiovascular protection.
Wilding et al. (NEJM): Landmark STEP 1 trial semaglutide 2.4mg achieved 14.9% mean weight loss vs 2.4% placebo at 68 weeks in 1,961 adults with obesity.
very strongLincoff et al. (NEJM): SELECT trial shows semaglutide 2.4mg reduces major adverse cardiovascular events by 20% in overweight/obese adults with established CVD.
very strongComprehensive analysis across STEP trials showing 14.9-17.4% weight loss, improved cardiometabolic risk factors, blood pressure, and quality of life with semaglutide 2.4mg.
very strongAroda et al. (JAMA): PIONEER trials demonstrate oral semaglutide achieves significant HbA1c and weight reductions, representing the first oral GLP-1RA for type 2 diabetes.
very strongEmerging evidence suggests semaglutide may have neuroprotective properties, with trials underway for Alzheimer's disease and other neurodegenerative conditions.
emergingFDA-approved for diabetes (Ozempic) and obesity (Wegovy). Well-studied long-term. GI side effects possible. Prescription required.
⚠️ For educational purposes only. Not medical advice. Consult a healthcare professional before using any peptide.
Start 0.25mg weekly, escalate monthly: 0.5 → 1.0 → 1.7 → 2.4mg. Oral: 3mg → 7mg → 14mg daily.
Last updated: 2026-01 · Laws change frequently. Verify current status in your jurisdiction.
Week 1
GI adjustment; appetite suppression significant from week 1
Weeks 2-4
0.5-1 lb/week weight loss; improved blood sugar control
Month 2-3
~10-14% body weight reduction; cardiovascular markers improving
Long-term
14.9% mean weight loss at 68 weeks (STEP 1 trial); 20% reduction in major CV events
| Side Effect | Incidence | Severity |
|---|---|---|
Nausea From STEP trials; mostly during escalation phase | ~44% of users | moderate |
Diarrhea | ~30% of users | mild |
Vomiting | ~24% of users | moderate |
Constipation | ~24% of users | mild |
Pancreatitis Discontinue if severe abdominal pain | Rare (<1%) | rare |
Incidence rates sourced from published clinical trial data where available; otherwise based on community research observations.
Maximum fat loss through multi-pathway metabolic optimization
Weekly Peptide Research
New studies · vendor alerts · protocol tips
No spam. Unsubscribe anytime. Research use only.